PAH News

Protein in Stem, Blood Cells May Be Marker of PAH Course, Severity

Levels of a protein found in certain blood cells indicate the severity and prognosis of pulmonary arterial hypertension (PAH), a study suggested. The findings could help achieve earlier diagnosis of PAH, which may improve clinical outcomes, researchers said. The study, “Circulating nerve growth factor receptor positive…

Fungus Used in Chinese Medicine Eased PAH Damage in Rat Model

Treatment with a fungus called Ophiocordyceps sinensis eased disease signs and improved survival in a rat model of pulmonary arterial hypertension (PAH), suggesting a potential to treat patients. The findings were in the study “Substantial involvement of TRPM7 inhibition in the therapeutic effect of Ophiocordyceps sinensis on…

Some PAH Patients May Benefit from Switch to Adempas

Intermediate-risk pulmonary arterial hypertension (PAH) patients may see their symptoms improve after switching from phosphodiesterase-5 inhibitors (PDE-5i) to Adempas (riociguat), results from the Phase 4 REPLACE clinical trial show. The transition to Adempas also appears to be a safer option than with PDE-5i maintenance therapy. The study, “Switching…

PulmoSIM Therapeutics Opens With Focus on Better Treating PAH

VeriSIM Life has opened PulmoSIM Therapeutics, its pharmaceutical subsidiary focused on developing treatments for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), before moving to other rare respiratory diseases. “We are thrilled to announce the launch of PulmoSIM as it demonstrates the indefinite capabilities of the VeriSIM’s…

Insmed Announces Top-line Results from Phase 1 Trial of TPIP

Top-line data from a Phase 1 clinical trial has found that treprostinil palmitil inhalation powder (TPIP) — a dry powder form of a treprostinil precursor that is being developed by Insmed for treating pulmonary arterial hypertension (PAH) — was safe and well-tolerated in healthy volunteers. Results also showed…